| 2.77 0.14 (5.32%) | 09-09 12:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.35  |
1-year : | 5.15 |
| Resists | First : | 3.72 |
Second : | 4.4 |
| Pivot price | 2.99 |
|||
| Supports | First : | 2.61 | Second : | 2.17 |
| MAs | MA(5) : | 2.78 |
MA(20) : | 3.14 |
| MA(100) : | 5.28 |
MA(250) : | 14.18 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 4.5 |
D(3) : | 3.6 |
| RSI | RSI(14): 32 |
|||
| 52-week | High : | 70.8 | Low : | 2.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DCOY ] has closed above bottom band by 22.3%. Bollinger Bands are 69.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.85 - 2.87 | 2.87 - 2.89 |
| Low: | 2.57 - 2.6 | 2.6 - 2.62 |
| Close: | 2.59 - 2.63 | 2.63 - 2.66 |
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Tue, 08 Sep 2026
Decoy is designing one antiviral for many viruses. Its CEO speaks Sept. 10. - Stock Titan
Wed, 02 Sep 2026
Director at Decoy Therapeutics (DCOY) awarded 2,000 restricted shares vesting in 2027 - Stock Titan
Wed, 02 Sep 2026
Decoy Therapeutics (DCOY) awards CEO 33,455 restricted shares - Stock Titan
Wed, 02 Sep 2026
Decoy Therapeutics (DCOY) CFO granted multi-year stock award - Stock Titan
Wed, 12 Aug 2026
Decoy Therapeutics: Q2 Earnings Snapshot - KTVB
Mon, 03 Aug 2026
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 586400 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 24 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.07e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 55.8 % |
| Return on Equity (ttm) | -73.4 % |
| Qtrly Rev. Growth | 227630 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -1478.17 |
| EBITDA (p.s.) | -2.91071e+006 |
| Qtrly Earnings Growth | 115.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.19 |
| Dividend | 0 |
| Forward Dividend | 10680 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|